# The Efficacy and Safty of Proton Pump Inhibitor (Lansoprazole)

Study · id `cardio:ct-nct05820048` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT05820048](<https://clinicaltrials.gov/study/NCT05820048>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT05820048

Browse, organ or system: Heart  
Browse, condition area: Coronary and vascular disease  

## In plain language

A phase 4 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 300 participants.

## Technical summary

Registry record NCT05820048. Randomized; single masking; primary purpose prevention. Start 2023-05-01 (anticipated); primary completion 2024-04-01 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; single masking; primary purpose prevention
- Phase: Phase 4
- Enrolled: 300 participants (planned count; ClinicalTrials.gov record NCT05820048, source copy `cardio:ctgov-nct05820048-2023-04-19`, retrieved 2026-10-26)
- Planned start: 2023-05-01 (anticipated) (ClinicalTrials.gov record NCT05820048, source copy `cardio:ctgov-nct05820048-2023-04-19`, retrieved 2026-10-26)
- Primary completion: 2024-04-01 (anticipated) (ClinicalTrials.gov record NCT05820048, source copy `cardio:ctgov-nct05820048-2023-04-19`, retrieved 2026-10-26)
- Completion: 2025-07-31 (anticipated) (ClinicalTrials.gov record NCT05820048, source copy `cardio:ctgov-nct05820048-2023-04-19`, retrieved 2026-10-26)
- Countries: Not reported
- Care setting: Not reported
- Registry status: "UNKNOWN" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct05820048-2023-04-19`, retrieved 2026-10-26)

## The registry's words

- Brief title: The Efficacy and Safty of Proton Pump Inhibitor (Lansoprazole)
- Acronym: PPI
- Condition: Coronary Artery Disease
- Intervention (Drug): Lansoprazole 15 mg
- Lead sponsor: Daejeon St. Mary's hospital
- Lead sponsor class: OTHER
- Collaborator: Jeil Pharmaceutical Co., Ltd.
- Collaborator class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Coronary artery disease (`cardio:coronary-artery-disease`)
- Registry lists this organization as the lead sponsor: Daejeon St. Mary's hospital (`cardio:org-daejeon-st-mary-s-hospital`)
- Registry lists this organization as a collaborator: Jeil Pharmaceutical Co., Ltd. (`cardio:org-jeil-pharmaceutical-co-ltd`)

## Provenance

Content hash: efe1db7c47d7aca39e30602f3dd696fc3ddc6d29ec6da585346406e6a79ca4ba
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
